Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Reports Q1 2025 Results and Updates Guidance
Summary
Jazz Pharmaceuticals plc announced its Q1 2025 financial results, reporting total revenues of $898 million. The company updated its 2025 financial guidance to reflect the Chimerix acquisition and certain Xyrem antitrust litigation settlements. Key product updates include revenue growth for Xywav and Epidiolex and the submission of a sNDA for Zepzelca. The company affirmed its 2025 total revenue guidance of $4.15 - $4.40 billion.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement